Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + epirubicin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Pemetrexed + epirubicin is a combination of two chemotherapeutic agents used in oncology. Pemetrexed is an antifolate antineoplastic agent that disrupts folate-dependent metabolic processes essential for cell replication by inhibiting enzymes such as thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, thereby blocking DNA and purine synthesis[1][4][5]. Epirubicin is an anthracycline topoisomerase II inhibitor that exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II activity, and generating free radicals leading to DNA damage[2][3][6]. Both drugs are administered intravenously and are primarily indicated for the treatment of various cancers. Pemetrexed is approved for non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma[1][4], while epirubicin is mainly used as adjuvant therapy in breast cancer with axillary node involvement but has broader antitumor activity[3][6].
- Brand names
- Epirubicin Hydrochloride Injection
02
Targets
GART (GAR transformylase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + epirubicin.